- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07469891
Een fase 1-studie van PRT12396 bij deelnemers met geselecteerde myeloproliferatieve neoplasieën
Een fase 1, open-label, multicenter, veiligheids- en werkzaamheidsstudie van PRT12396 bij deelnemers met polycythemia vera en myelofibrose
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This first-in-human, open-label, multi-center Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF). Eligible MF populations include participants with intermediate-1, intermediate-2, or high-risk primary MF, as well as post-polycythemia vera MF or post-essential thrombocythemia MF, with evidence of disease burden based on splenomegaly.
The study is conducted in two parts:
Part 1 (dose escalation) evaluates escalating oral doses of PRT12396 to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]).
Part 2 (dose expansion) enrolls additional participants at selected dose level(s) to further characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in the PV and MF populations.
Approximately up to 100 participants are planned for enrollment across both parts of the study.
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Study Contact (Please Do Not Disclose Personal Information)
- Telefoonnummer: See Email
- E-mail: clinicaltrials@preludetx.com
Studie Locaties
-
-
South Australia
-
Adelaide, South Australia, Australië, 5000
- Werving
- Royal Adelaide Hospital
-
-
Victoria
-
Clayton, Victoria, Australië, 3168
- Werving
- Monash Health, Monash Medical Centre
-
-
Western Australia
-
Nedlands, Western Australia, Australië, 6009
- Werving
- One Clinical Research
-
-
-
-
-
Nice, Frankrijk, 06200
- Werving
- Nice University Medicâl Center (CHU Nice, Hôpital Archet 1)
-
Paris, Frankrijk, 75010
- Werving
- Saint-Louis Hospital
-
Toulouse, Frankrijk, 31059
- Werving
- Oncopole Claudius Regaud
-
-
-
-
-
Florence, Italië, 50134
- Werving
- Azienda Ospedaliero Universitaria Careggi
-
-
-
-
-
Barcelona, Spanje, 08036
- Werving
- Hospital Clinic de Barcelona
-
Madrid, Spanje, 28034
- Werving
- Hospital Universitario Ramon y Cajal
-
Madrid, Spanje, 28041
- Werving
- Hospital Universitario 12 de Octubre
-
Valencia, Spanje, 46010
- Werving
- Hospital Clínico Universitario de Valencia
-
-
-
-
California
-
Los Angeles, California, Verenigde Staten, 90095
- Werving
- UCLA Ronald Reagan Medical Center
-
Sacramento, California, Verenigde Staten, 95817
- Werving
- University of California, Davis Comprehensive Cancer Center
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80218
- Werving
- Colorado Blood Cancer Institute
-
-
Florida
-
Coral Springs, Florida, Verenigde Staten, 33065
- Werving
- BRCR Global - Coral Springs
-
Miami, Florida, Verenigde Staten, 33136
- Werving
- Sylvester Comprehensive Cancer Center
-
Tampa, Florida, Verenigde Staten, 33612
- Werving
- Moffitt Cancer Center
-
-
Michigan
-
Grand Rapids, Michigan, Verenigde Staten, 49546
- Werving
- START Midwest, LLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Werving
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- Tristar BMT
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- Tennessee Oncology, PLLC - Investigational Drug Services
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- The University of Texas, MD Anderson Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures.
- Confirmed diagnosis of PV or MF according to WHO 2016 or revised ICC/WHO 2022 criteria
- Documented presence of a JAK2 V617 mutation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Estimate life expectancy of ≥12 weeks per investigator assessment.
- Negative serum or urine pregnancy test and agree to use contraception or maintain true abstinence.
- Adequate organ function and bone marrow reserves (hematology, renal, and hepatic)
Exclusion Criteria:
- History of another malignancy within 3 years prior to enrollment, except for malignancy considered cured with low risk of recurrence.
- Clinically significant anemia due to nutritional deficiency or hemolytic disorders.
- Active or uncontrolled infection requiring systemic therapy or hospitalization.
- Any other medical or psychiatric conditions that, in the Investigator's judgment, would increase risk or interfere with study participation or interpretation of results.
- Clinically significant or uncontrolled medical conditions, including active infection or cardiovascular disease, that would increase risk or interfere with study participation.
- Unresolved toxicity Grade >1 from prior anticancer therapy, except for alopecia or peripheral neuropathy Grade ≤2.
- Pregnancy or breastfeeding
- Known sensitivity or contraindication to any component of study, or the excipients of study treatment.
- Prior systemic therapy for PV or MF, prior or planned allogeneic hematopoietic stem-cell transplantation, recent major surgery, prior splenectomy or prior splenic irradiation, or use of hematopoietic growth factors within protocol-defined washout periods.
- Use of strong or moderate cytochrome P450 (CYP) 3A4 inhibitor or inducer, sensitive CYP3A substrates with narrow therapeutic range, or acid-reducing agents that cannot be discontinued prior to study treatment.
- Participation in another interventional clinical study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: PRT12396: MF
Participants with myelofibrosis receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE) |
PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals. |
|
Experimenteel: PRT12396: PV
Participants with polycythemia vera receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE) |
PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Dose limiting toxicity (DLT) of PRT12396
Tijdsspanne: Through cycle 1 (4 weeks)
|
Incidence of dose limiting toxicities, defined according to protocol-specified criteria |
Through cycle 1 (4 weeks)
|
|
Incidence and severity of Adverse events
Tijdsspanne: Through study completion, an average of 2 years
|
Incidence and severity of treatment-emergent adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 6.0 |
Through study completion, an average of 2 years
|
|
Adverse Events Leading to Dose Modifications or Discontinuation
Tijdsspanne: Through study completion, an average of 2 years
|
Incidence of AEs leading to dose reductions, dose interruptions, treatment discontinuations, and clinically significant laboratory abnormalities |
Through study completion, an average of 2 years
|
|
Maximum tolerated dose (MTD) and Recommended Dose(s) for Expansion (RDE[s]) of PRT12396
Tijdsspanne: Through study completion, an average of 2 years
|
Determination of the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]) based on evaluation of DLTs, safety, and tolerability data |
Through study completion, an average of 2 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Hematologic Response Rate (PV)
Tijdsspanne: Through study completion, an average of 2 years
|
Proportion of participants with polycythemia vera (PV) achieving best overall hematologic response (complete hematologic response or partial hematologic response) from the overall response assessments by Investigator |
Through study completion, an average of 2 years
|
|
Duration of Hematologic Response (PV)
Tijdsspanne: Through study completion, an average of 2 years
|
Duration of hematologic response in PV participants, defined as the time from first documented response (best overall hematologic response) to disease progression or death, whichever comes first |
Through study completion, an average of 2 years
|
|
Hematocrit Control Without Phlebotomy Requirements (PV)
Tijdsspanne: Through study completion, an average of 2 years
|
Proportion of PV participants achieving and maintaining hematocrit control without phlebotomy, time to first phlebotomy, and frequency of phlebotomy |
Through study completion, an average of 2 years
|
|
Spleen Response (MF)
Tijdsspanne: Through study completion, an average of 2 years
|
Assessment of spleen response including proportion achieving protocol-specified reduction in spleen volume, time to spleen response, duration of spleen response, and reduction in palpable spleen length |
Through study completion, an average of 2 years
|
|
Change from Baseline in Hemoglobin (MF)
Tijdsspanne: Through study completion, an average of 2 years
|
Change from baseline in hemoglobin levels in MF participants |
Through study completion, an average of 2 years
|
|
Change from Baseline in Platelet Count (MF)
Tijdsspanne: Through study completion, an average of 2 years
|
Change from baseline in platelet count in MF participants |
Through study completion, an average of 2 years
|
|
Change from Baseline in Absolute Neutrophil Count (MF)
Tijdsspanne: Through study completion, an average of 2 years
|
Change from baseline in absolute neutrophil count in MF participants |
Through study completion, an average of 2 years
|
|
Transfusion Independence (MF)
Tijdsspanne: Through study completion, an average of 2 years
|
Proportion achieving transfusion independence and duration of transfusion independence as defined by protocol criteria |
Through study completion, an average of 2 years
|
|
Maximum Observed Plasma Concentration (Cmax)
Tijdsspanne: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Maximum observed plasma concentration will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Time To Maximum Concentration (Tmax)
Tijdsspanne: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Time to maximum concentration will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Area under the plasma concentration versus time curve (AUC)
Tijdsspanne: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Area under the plasma concentration-time curve will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Terminal Elimination Half-life (T1/2)
Tijdsspanne: Cycle 1 Day 1
|
Terminal elimination half-life will be calculated using non-compartmental analysis |
Cycle 1 Day 1
|
|
Steady State Trough Concentrations
Tijdsspanne: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Steady state trough concentrations will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Clearance
Tijdsspanne: Cycle 1 Day 1
|
Clearance will be calculated using non-compartmental analysis |
Cycle 1 Day 1
|
|
Accumulation
Tijdsspanne: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Accumulation will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
Tijdsspanne: Through study completion, an average of 2 years
|
Patient-reported outcomes assessed using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS), evaluated as change from baseline at protocol-specified time points. The MPN SAF TSS is a validated questionnaire in which individual symptoms are scored using a numeric rating scale ranging from 0 to 10, with 0 indicating no symptoms and 10 indicating the worst imaginable symptoms; higher scores indicate greater symptom severity. |
Through study completion, an average of 2 years
|
|
Patient Global Impression of Change (PGI-C)
Tijdsspanne: Through study completion, an average of 2 years
|
Participant reported outcomes assessed using the Patient Global Impression of Change (PGI-C), evaluated at protocol-specified time points. The PGI C is a global assessment scale in which participants rate their overall change in condition since baseline using a 7 point ordinal scale ranging from "very much improved" to "very much worse," with lower scores indicating improvement and higher scores indicating worsening of symptoms. |
Through study completion, an average of 2 years
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- PRT12396-01
- 2026-525484-40-00 (Ctis)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .